180 related articles for article (PubMed ID: 18701498)
21. Complement-dependent P-selectin expression and injury following ischemic stroke.
Atkinson C; Zhu H; Qiao F; Varela JC; Yu J; Song H; Kindy MS; Tomlinson S
J Immunol; 2006 Nov; 177(10):7266-74. PubMed ID: 17082645
[TBL] [Abstract][Full Text] [Related]
22. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
23. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
24. Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU).
Jha P; Sohn JH; Xu Q; Wang Y; Kaplan HJ; Bora PS; Bora NS
J Immunol; 2006 Jun; 176(12):7221-31. PubMed ID: 16751365
[TBL] [Abstract][Full Text] [Related]
25. Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth.
Banadakoppa M; Pennington K; Balakrishnan M; Yallampalli C
PLoS One; 2020; 15(8):e0236968. PubMed ID: 32745140
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis.
Mühlfeld AS; Segerer S; Hudkins K; Farr AG; Bao L; Kraus D; Holers VM; Quigg RJ; Alpers CE
Kidney Int; 2004 Apr; 65(4):1214-23. PubMed ID: 15086460
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.
Kim DD; Miwa T; Kimura Y; Schwendener RA; van Lookeren Campagne M; Song WC
Blood; 2008 Aug; 112(4):1109-19. PubMed ID: 18524992
[TBL] [Abstract][Full Text] [Related]
28. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer.
Caragine TA; Okada N; Frey AB; Tomlinson S
Cancer Res; 2002 Feb; 62(4):1110-5. PubMed ID: 11861390
[TBL] [Abstract][Full Text] [Related]
29. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice.
Banda NK; Tomlinson S; Scheinman RI; Ho N; Ramirez JR; Mehta G; Wang G; Vu VP; Simberg D; Kulik L; Holers VM
Front Immunol; 2020; 11():575154. PubMed ID: 33178202
[TBL] [Abstract][Full Text] [Related]
30. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.
Kang HJ; Bao L; Xu Y; Quigg RJ; Giclas PC; Holers VM
Clin Exp Immunol; 2004 May; 136(2):194-9. PubMed ID: 15086380
[TBL] [Abstract][Full Text] [Related]
31. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
[TBL] [Abstract][Full Text] [Related]
32. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.
Kopf M; Abel B; Gallimore A; Carroll M; Bachmann MF
Nat Med; 2002 Apr; 8(4):373-8. PubMed ID: 11927943
[TBL] [Abstract][Full Text] [Related]
33. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo.
Ohta R; Kondor N; Dohi N; Tomlinson S; Imai M; Holers VM; Okada H; Okada N
J Immunol; 2004 Jul; 173(1):205-13. PubMed ID: 15210776
[TBL] [Abstract][Full Text] [Related]
34. Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.
Ortiz-Bonilla CJ; Uccello TP; Gerber SA; Lord EM; Messing EM; Lee YF
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328324
[TBL] [Abstract][Full Text] [Related]
35. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.
Imai M; Landen C; Ohta R; Cheung NK; Tomlinson S
Cancer Res; 2005 Nov; 65(22):10562-8. PubMed ID: 16288049
[TBL] [Abstract][Full Text] [Related]
36. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
[TBL] [Abstract][Full Text] [Related]
37. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
38. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
39. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure.
Schiller B; Cunningham PN; Alexander JJ; Bao L; Holers VM; Quigg RJ
J Am Soc Nephrol; 2001 Jan; 12(1):71-79. PubMed ID: 11134252
[TBL] [Abstract][Full Text] [Related]
40. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
